Published in Aliment Pharmacol Ther on March 01, 2004
Production of therapeutic antibodies with controlled fucosylation. MAbs (2009) 1.17
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther (2009) 1.17
Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer (2009) 1.04
Role of genetics in the diagnosis and prognosis of Crohn's disease. World J Gastroenterol (2012) 1.01
Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies. Front Immunol (2014) 0.98
Predicting response to Anti-TNF Agents for the treatment of crohn's disease. Therap Adv Gastroenterol (2009) 0.96
The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation. Glycobiology (2008) 0.95
Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol (2010) 0.94
Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol (2012) 0.91
Pharmacogenetics: implications for therapy in rheumatic diseases. Nat Rev Rheumatol (2011) 0.90
Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol (2006) 0.90
FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics (2013) 0.88
Fc gamma receptor CD64 modulates the inhibitory activity of infliximab. PLoS One (2012) 0.86
Association of TNF and FcγRΙΙΙA gene polymorphisms with differential response to infliximab in a Greek cohort of Crohn's disease patients. Ann Gastroenterol (2011) 0.85
Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. Immunology (2005) 0.84
Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size. MAbs (2010) 0.81
How does genotype influence disease phenotype in inflammatory bowel disease? Inflamm Bowel Dis (2013) 0.81
Role of genetics in the diagnosis and prognosis of Crohn's disease. World J Gastroenterol (2011) 0.79
The role of pharmacogenetics in nonmalignant gastrointestinal diseases. Nat Rev Gastroenterol Hepatol (2012) 0.79
Current stage in inflammatory bowel disease: What is next? World J Gastroenterol (2015) 0.78
Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices. BioDrugs (2016) 0.77
Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther (2016) 0.76
Interindividual variability in the concentration-effect relationship of antilymphocyte globulins - a possible influence of FcgammaRIIIa genetic polymorphism. Br J Clin Pharmacol (2007) 0.75
Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease. Am J Gastroenterol (2016) 0.75
Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling. AAPS J (2016) 0.75
The search continues: finding who will and who will not respond to infliximab. Inflamm Bowel Dis (2005) 0.75
Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. PLoS One (2014) 0.75
Pharmacogenomics of IBD Therapies. Gastroenterol Hepatol (N Y) (2007) 0.75
Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci (2017) 0.75
Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease. World J Gastroenterol (2017) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut (2006) 8.08
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut (2008) 4.41
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut (2001) 4.23
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology (1998) 4.08
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther (2012) 3.59
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut (2006) 3.57
Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut (2009) 3.50
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut (2008) 3.14
Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut (2006) 3.00
Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum (2013) 2.87
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology (2001) 2.81
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology (1999) 2.80
Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Aliment Pharmacol Ther (2012) 2.74
Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut (1984) 2.70
Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut (2008) 2.60
Genetic analyses of chromosome 12 loci in Crohn's disease. Gut (2000) 2.30
Current status of genetics research in inflammatory bowel disease. Genes Immun (2005) 2.29
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther (2015) 2.25
PillCam colon capsule endoscopy compared with colonoscopy for colorectal tumor diagnosis: a prospective pilot study. Endoscopy (2006) 2.24
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol (1998) 2.20
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut (2009) 2.20
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology (1997) 2.18
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology (1996) 2.08
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol (2001) 2.06
Predicting relapse in Crohn's disease: a biopsychosocial model. Gut (2008) 2.01
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol (1995) 1.99
Automated neonatal seizure detection mimicking a human observer reading EEG. Clin Neurophysiol (2008) 1.96
Randomised open controlled trial of colloidal bismuth subcitrate tablets and cimetidine in the treatment of duodenal ulcer. Gut (1980) 1.95
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther (2001) 1.94
Spontaneous secretion of interferon gamma and interleukin 4 by human intraepithelial and lamina propria gut lymphocytes. Gut (1998) 1.88
A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol (1997) 1.85
Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology (1997) 1.84
In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology (1998) 1.74
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum (2001) 1.70
The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). Aliment Pharmacol Ther (2011) 1.69
Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol (1997) 1.69
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther (2013) 1.69
Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut (2005) 1.65
Histopathology of intestinal inflammation related to reactive arthritis. Gut (1987) 1.64
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther (2004) 1.62
Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol (1998) 1.60
Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc (1999) 1.59
Home parenteral nutrition in adults: a multicentre survey in Europe in 1993. Clin Nutr (1996) 1.58
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther (2014) 1.56
Comparison of total and compartmental gastric emptying and antral motility between healthy men and women. Eur J Nucl Med (1998) 1.56
Validation of a new automated neonatal seizure detection system: a clinician's perspective. Clin Neurophysiol (2011) 1.52
The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol (1995) 1.51
Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia (1997) 1.50
The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun (2007) 1.50
[Celiac disease in adults: new aspects]. Rev Med Interne (2004) 1.49
Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet (1990) 1.49
Comparative analysis of detoxification enzymes in Acyrthosiphon pisum and Myzus persicae. Insect Mol Biol (2010) 1.48
Crohn's disease with adenocarcinoma and dysplasia. Macroscopical, histological, and immunohistochemical aspects of two cases. Am J Surg Pathol (1989) 1.47
The wirsungorrhagies: causes and management in 14 patients. Endoscopy (1998) 1.46
Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2010) 1.45
Survey on legislation and funding of home artificial nutrition in different European countries. Clin Nutr (2001) 1.45
Offering excess oocyte aspiration and vitrification to patients undergoing stimulated artificial insemination cycles can reduce the multiple pregnancy risk and accumulate oocytes for later use. Hum Reprod (2010) 1.45
Influence of nutritional substrates on the formation of volatiles by the fecal flora. Gastroenterology (1991) 1.45
IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol (2000) 1.45
Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol (1991) 1.45
Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther (2005) 1.45
The Dutch guidelines for treatment with infliximab for Crohn's disease. Neth J Med (2006) 1.44
The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol (1995) 1.44
Delayed toxicity in acute ethanol-methanol copoisoning in a chronic alcohol abuser: usefulness of continuous 4-methylpyrazole (fomepizole) infusion. Intensive Care Med (2000) 1.43
Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: a prospective longterm analysis. Gut (1995) 1.42
Colon capsule endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy (2012) 1.42
Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr (1999) 1.42
Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet (2000) 1.42
Gastric emptying of solids in cirrhotic and peritoneal dialysis patients: influence of peritoneal volume load. Eur J Gastroenterol Hepatol (2002) 1.41
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 1.41